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Background: Chronic obstructive pulmonary disease (COPD) and asthma have different
diagnostic criteria and treatment paradigms. Both are common and can occur in the same
patient. We sought to determine the spirometric effects of tiotropium in COPD patients
with concomitant asthma.
Methods: A 12-week randomized, double-blind, placebo-controlled, parallel group trial
with tiotropium 18mcg daily was performed. Patients continued usual respiratory
medications except for inhaled anticholinergics. Inclusion criteria: Physician diagnosis of
COPD and asthma, age X40 years, smoking 410 pack years, post-bronchodilator forced
expiratory volume in 1s (FEV1)o80% predicted, FEV1/forced vital capacity (FVC)o70%,
X12%, and X200ml increase in FEV1 following inhaled bronchodilator, treatment with
inhaled steroids X1 year. Spirometry was measured serially for 6 h on days 1, 29 and 85.
Results: Four hundred and seventy-two patients were randomized. Baseline character-
istics were balanced. Mean age ¼ 59.6 years, 61.4% were men, and FEV1 ¼ 1.55 l (53.0%
predicted). Improvements at 12 weeks with tiotropium were observed for the primary
endpoint FEV1 area under the curve (AUC) from 0 to 6 h (difference ¼ 186724ml,
po0.001) and for morning pre-dose FEV1 (difference ¼ 98723ml, po0.001). Significant
differences in favor of tiotropium were observed for pre-dose FVC (differen-
ce ¼ 128734ml, po0.001) and FVC AUC 0–6 h (difference ¼ 232735ml, po0.001).
Compared to baseline, the mean weekly number of daily puffs of prn salbutamol wasElsevier Ltd. All rights reserved.
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l capacity; FEV1, forced expiratory volume in 1s; GINA, Global Initiative for Asthma; GOLD, Global
Disease; MDI, metered dose inhaler; PEFR, peak expiratory flow rate; SEM, standard error of the mean
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Improvements with tiotropium in COPD patients with concomitant asthma 51reduced by 0.0570.12 puffs/day in the placebo group and by 0.5070.12 puffs/day in the
tiotropium group at week 12 (po0.05).
Conclusions: Patients with COPD and concomitant asthma achieve spirometric improve-
ments with tiotropium along with symptomatic benefit as seen by reduced need for rescue
medication.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is defined as
a disease state characterized by airflow limitation that is not
fully reversible.1 Asthma is defined as a chronic inflamma-
tory disorder of the airways that is associated with airway
hyperresponsiveness, which leads to recurrent symptoms
that are usually associated with airflow obstruction within
the lung that is often reversible either spontaneously or with
treatment.2 Despite differing etiologies, pathophysiology,
and clinical presentations, it is estimated that 10–20% of
patients have features of both diseases COPD and asthma.3,4
Management strategies for asthma and COPD differ and
current guidelines reinforce the need to determine a specific
diagnosis and directing the subsequent treatment accord-
ingly.1,2 Inhaled corticosteroids are well recognized as
essential treatment in patients with asthma who have
symptoms on a regular basis; however, in patients with COPD,
inhaled steroids are considered only for patients with at least
severe disease and repeated exacerbations.1,2 Anticholiner-
gics such as ipratropium or tiotropium remain a first line
treatment option in COPD, while their role in the treatment of
asthma is limited. Studies indicate that anticholinergics may
be additive to b-agonists in providing relief to patients with
acute asthma.5,6 A recent trial suggested that ipratropium
alone could be used for symptom relief in asthma.7
While there is presently a large body of data supporting the
efficacy of tiotropium in patients with COPD, to date, patients
with COPD and concomitant asthma have been excluded from
the long-term tiotropium COPD clinical trials.8–10 The objec-
tive of this trial was to evaluate the efficacy and safety of
tiotropium inhalation capsules 18mcg once daily administered
via the HandiHalers in a subgroup of patients with COPD who
have a concomitant diagnosis of asthma.
Methods and materials
The primary objective of this study was to demonstrate the
superiority of tiotropium 18mcg once daily administered via
the HandiHalers compared to placebo in the treatment of
patients with COPD and a concomitant diagnosis of asthma
(trial 205.301). The primary efficacy endpoint was the
change in forced expiratory volume in 1s (FEV1) area under
the curve over 6 h (FEV1 AUC06h) after 12 weeks of
randomized treatment.
Study design
The study was a 12-week, multi-center, multi-national,
prospective, randomized, placebo-controlled, double-blind
clinical trial. Following an initial screening, patients entered
a 2-week run-in period. Patients treated with commerciallyavailable tiotropium were switched to ipratropium metered
dose inhaler (MDI) qid 4 weeks prior to screening and continued
treatment with ipratropium during the run-in period. Patients
were allowed to continue treatment with long-acting inhaled
b-agonists, inhaled corticosteroids, oral steroids (p10mg/day
prednisone or equivalent), theophyllines, leukotriene antago-
nists, and cromones as concomitant medication. Salbutamol
was provided for as-needed acute symptom relief. At baseline,
and 4 and 12 weeks post-randomization, spirometry was
conducted 30 and 10min prior to the administration of the
study drug and 30, 60min, 2, 3, 4, and 6h post-dosing.
Patients were not allowed to take anticholinergic therapy
other than study drug during the randomization period.
Wash-out periods prior to spirometry on clinic days were as
follows: long-acting inhaled b-agonists (including combina-
tion products) (24 h), theophylline preparations (24 h), and
short-acting b-agonists (8 h).
The protocol was approved by ethics committees and/or
institutional review boards for all participating centers. All
patients signed written informed consent.
Patient population
Patients were required to have a physician diagnosis of
asthma (before the age of 30 years), a diagnosis of COPD,1,11
post-bronchodilator FEV1o80% predicted normal and a post-
bronchodilator ratio of FEV1/FVC (forced vital capaci-
ty)o70%. Other inclusion criteria were: smoking history
410 pack-years, age X40 years, treatment with inhaled
corticosteroids for X1-year prior to study entry, and an
acute bronchodilator response X200ml and X12% of pre-
bronchodilator FEV1 at the screening visit or documented
during the past 5 years in the patient clinic records.
Spirometry
Spirometry equipment and techniques conformed to the
criteria of the ATS.12 The highest FEV1 and the highest FVC
obtained from three acceptable manoeuvres were recorded.
For each patient, pulmonary function testing was to start
between 7 and 10 a.m. At the beginning of the run-in period,
spirometry was performed before and 30min after 400mcg
inhaled salbutamol. At subsequent visits, FEV1 and FVC were
obtained at 30 and 10min prior to, and 30, 60min, 2, 3, 4,
and 6 h after drug administration.
Peak expiratory flow rates (PEFR) and symptom
relief
Patients measured and recorded their PEFR in the morning
(pre-dose) and in the evening. The patient took three
readings per measurement and documented the highest in
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actuations of salbutamol which he/she had needed per day
in the daily diary card.
Data analysis
The area under the curve (AUC) for FEV1 and FVC was
calculated using the trapezoidal rule and normalized by
division by 6 h. Baseline measurement was defined as mean
of the two pre-dose measurements on day 1. For all diary
endpoints, baseline was defined as the average of the data
obtained in the week immediately preceding randomization.
Testing was performed by comparing the least-square
means, adjusted for treatment differences, pooled center
differences, and baseline using the two sided t-test with the
mean squared error as error term. The difference between
the two treatment groups regarding the primary endpoint
FEV1 AUC06h was tested by an analysis of covariance using
the linear model with terms for treatment, pooled center,
and baseline values of the primary variable as covariate.
Continuous secondary efficacy endpoints were descrip-
tively evaluated using, when appropriate, the models and
methods described for the primary endpoint. The calcula-
tion of weekly means for PEFR and as-needed salbutamol
were based on at least four data points. Imputations rules
applied if fewer than four data points were available. For
missing values, in general, the last observation was carried
forward, or in case missing data was due to worsening of
disease, than the worst observation was carried forward.
Data are expressed as means7SEM unless otherwise
specified. Statistical significance was considered at po0.05.
According to sample size calculations (nQuery Advisors
Version 4.0), a sample of 410 patients (205 per randomized
treatment group) would be able to detect a 106ml
difference between the randomized treatment groups at
5% level of significance (two sided) with at least 90% power
using a two-tailed t-test. Assumptions were based on
previous clinical trials with tiotropium.8,9
Results
The trial was conducted in 67 centers distributed within
Belgium, Canada, Germany, Denmark, France, Italy, the
Netherlands, and South Africa. A total of 566 patients were
enrolled. Of those, 472 patients were considered eligible
after the run-in period based on the inclusion and exclusion
criteria and were randomized to either 18 mg tiotropium
(228 patients) or matching placebo (244 patients). Ninety-
four enrolled patients were not randomized. A total of
456 patients (96.6%) completed the entire planned observa-
tion time (placebo: 233 patients, 95.5%; tiotropium:
223 patients, 97.8%). Sixteen randomized patients (3.4%)
discontinued prematurely (i.e. before day 85). The percen-
tage of patients who withdrew was higher in the placebo
group (11 patients, 4.5%) than in the tiotropium group
(5 patients, 2.2%).
Patient characteristics
The mean age of the population was 59.6 years, 61.4% were
men, and the mean FEV1 was 1.55 l (53.0% predicted). Themean duration of COPD and asthma was 9.2 and 43.2 years,
respectively. Baseline characteristics were similar between
the treatment groups (Table 1). Mean baseline FEV1
was 1.57 l in the tiotropium group and 1.53 l in the placebo
group. PEFR, as-needed salbutamol and concomitant
maintenance pulmonary medications are recorded in
Tables 1 and 2.
Spirometry
Improvements at 12 weeks with tiotropium were observed
for the primary endpoint FEV1 AUC 0–6 h (difference ¼
186724ml, po0.001) and for pre-dose FEV1 (difference ¼
98723ml, po0.001). Significant differences in favor of
tiotropium were observed for pre-dose FVC (difference ¼
128734ml, po0.001) and FVC AUC 0–6 h (difference ¼
232735ml, po0.001). Peak FEV1 and peak FVC improve-
ments relative to placebo were 188725 and 254737ml,
respectively (po0.001). Increases in spirometry outcomes
were observed with the first dose and at 4 weeks. Changes in
spirometry over 6 h at baseline and at week 12 are displayed
in Figures 1 and 2.
Peak expiratory flow rate
Weekly average PEFR improved on treatment with tiotro-
pium. Daily dosing with tiotropium led to an increase in
absolute morning and evening values. The mean difference
to placebo in the change from baseline at week 12 was
20.374.3 l/min (po0.0001) for the morning measurement
and 23.674.2 l/min (po0.0001) for the evening measure-
ment (Figure 3).
Rescue requirement for salbutamol
Compared to baseline, mean weekly number of daily puffs of
as-needed salbutamol was reduced by 0.0570.12 puffs/day
in the placebo group and by 0.5070.12 puffs/day in the
tiotropium group (difference ¼ 0.4570.17, po0.05) at
week 12 (Figure 4).
Adverse events
Overall, 176 patients (37.3%) of the patients reported
adverse events during the treatment period with a similar
frequency for the two treatments (placebo: 36.5%; tiotro-
pium: 38.2%). The most frequent adverse events on
treatment were lower respiratory system disorders (place-
bo: 20.1%; tiotropium: 12.7%), upper respiratory system
disorders (placebo: 5.7%; tiotropium: 13.2%), and gastro-
intestinal disorders (placebo: 5.7%; tiotropium: 9.6%). The
most commonly reported gastrointestinal adverse event was
dry mouth (placebo: 1.6%; tiotropium: 3.9%). Other system
organ classes were noted with overall frequencies below 4%.
Within lower respiratory system disorders, the most
common adverse events were exacerbations of the under-
lying diseases COPD and asthma (placebo: 28 patients,
11.5%; tiotropium: 15 patients, 6.6%). The frequency of
patients with COPD exacerbations was lower in the
tiotropium group (placebo: 26 patients, 10.7%; tiotropium:
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Table 2 Maintenance pulmonary medication (% of population) used prior to enrolment in the tiotropium and placebo groups.
Placebo, n ¼ 244 Tiotropium, n ¼ 228 Total, n ¼ 472
Total taking pulmonary medication 99.6 98.2 98.9
b-Adrenergics (long-acting/inhaled) 68.4 75.0 71.6
Anticholinergics (short-acting/inhaled) 21.3 16.2 18.9
Theophyllines 19.7 16.2 18.0
Anticholinergics (long-acting/inhaled) 11.5 10.1 10.8
Leukotriene receptor antagonists 5.7 5.7 5.7
Steroids (oral) 5.3 3.5 4.4
b-Adrenergics (oral) 0.4 1.8 1.1
Inhaled steroid use was an inclusion criteria.
Table 1 Baseline characteristics of patients in the tiotropium and placebo groups.
Placebo, n ¼ 244 Tiotropium, n ¼ 228 Total, n ¼ 472
Age (years) 60.2 (9.4) 59.1 (9.8) 59.6 (9.6)
Male (%) 149 (61.1) 141 (61.8) 290 (61.4)
Duration of COPD (years) 9.1 (6.8) 9.2 (7.2) 9.2 (7.0)
Duration of asthma (years) 43.9 (13.9) 42.5 (14.3) 43.2 (14.1)
Current smoker (%) 99 (40.6) 103 (45.2) 202 (42.8)
Smoking history (pack-years) 33.6 (16.8) 33.9 (17.3) 33.7 (17.0)
FEV1 (l) 1.53 (0.48) 1.57 (0.53) 1.55 (0.51)
FEV1 (% predicted) 53.3 (13.7) 52.7 (13.5) 53.0 (13.6)
FVC (l) 2.86 (0.86) 2.91 (0.87) 2.88 (0.86)
FEV1/FVC (%) 54.5 (11.4) 54.3 (11.3) 54.4 (11.3)
FEV1 increase from baseline (%) to salbutamol 400 mg 19.5 (13.8) 19.8 (14.4) 19.6 (14.1)
AM PEFR (l/min) 282.5 (85.8) 294.0 (102.3) 288.0 (94.2)
PM PEFR (l/min) 292.8 (82.3) 307.1 (99.0) 299.7 (91.0)
Day time salbutamol use (puffs/day) 1.88 (2.08) 1.76 (1.97) 1.82 (2.03)
Night time use of salbutamol (puffs/night) 0.60 (1.12) 0.55 (1.04) 0.58 (1.08)
Total use of salbutamol (puffs/24 h) 2.47 (2.77) 2.31 (2.62) 2.40 (2.70)
Data are expressed as means (SD) or proportions.
Weekly average.
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exacerbation was similar (placebo: 8 patients (3.3%),
tiotropium: 6 patients (2.6%)). Two patients died during
the trial, both were receiving placebo (COPD exacerbation,
respiratory failure). A patient who had received tiotropium
was reported to have died from a pneumothorax and COPD
exacerbation approximately 6 months after the last dose of
study drug.Discussion
The present 12-week trial is the first randomized, double-
blind, controlled clinical study to have investigated the
efficacy and safety of tiotropium 18mcg once daily in
patients with COPD and concomitant asthma. Tiotropium led
to a significant improvement in FEV1 measured over 6 h as
well as FVC. Efficacy was further corroborated by the
observed increase in PEFR and decrease in the use of rescue
medication in patients treated with tiotropium. The results
of the safety evaluation suggested a decrease in exacerba-tions with tiotropium, a finding consistent with previously
reported clinical trials.8–10,13
Previously published reports indicate that there is likely a
sizeable number of patients over the age of 50 years with
obstructive airway disease to carry the dual diagnosis of
asthma and COPD.4,14 Debate remains as to whether COPD
develops from asthma (referred to as the Dutch hypoth-
esis)15 or whether asthma and COPD are completely
independent disorders (referred to as the British hypoth-
esis).15–19 However, there is little debate that the diseases
remain histologically different, have different physiologic
abnormalities, differ in clinical manifestations and perhaps
most importantly, have different responses to pharmacolo-
gic intervention.1,2,20,21,23 One of the more relevant
therapeutic differences is the recommended preference
for inhaled corticosteroids as first-line maintenance treat-
ment in asthma, and for long-acting inhaled bronchodilators
in COPD.
Tiotropium is a once daily inhaled anticholinergic that has
demonstrated improvements in spirometry, lung volumes,
dyspnea, health-related quality of life, and exercise
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Figure 1 Time course of FEV1 (l) over 6 h at baseline (a) and
after week 12 (b) in the tiotropium and placebo groups
(po0.001 for all time points).
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Figure 2 Time course of FVC (l) over 6 h at baseline (a) and
after week 12 (b) in the tiotropium and placebo groups
(po0.001 for all time points).
H. Magnussen et al.54tolerance.7–9,13 In these trials, patients with a history of
asthma were excluded from participation in an effort to
assure that tiotropium was being evaluated in a patient
population with COPD. Therefore, data on efficacy and
safety in patients with both disorders have not been
generated from randomized, blinded, controlled clinical
trials. It could be argued that there it is obvious that these
patients should be treated for both disorders and there is no
need to study the benefits of an established treatment for a
broad population of patients with COPD. Nevertheless, in
the absence of specific data, the answer is based on indirect
evidence. There may be unanticipated interactions of
asthma and COPD along with other concomitant therapies
that could diminish or possibly enhance responses to
medications from another class. Ceiling effects are also
unclear. It is therefore reasonable to conduct prospective
trials specifically designed for such patients to confirm the
supposition that COPD patients with asthma respond to
tiotropium.
One of the critical factors in the present study is the
accuracy of the diagnosis of asthma and COPD. The diagnosis
of COPD appears to be easily defendable; patients with fixed
airflow limitation, age of at least 40 years, history of
smoking, and a physician diagnosis of COPD. The diagnosis is
consistent with COPD guidelines. However, it is recognized
that there may be some limitations regarding the diagnosisof asthma in this study. Challenge testing for airway
hyperreactivity was not performed although patients were
required to show acute responsiveness to a short-acting
inhaled b-agonist. This in itself can be regarded as non-
specific given that patients with COPD can demonstrate
acute responsiveness to short-acting bronchodilators.24,25 In
a retrospective analysis of 1 year clinical trials with
tiotropium in COPD, tiotropium was efficacious irrespective
of short-term improvements in FEV1 of at least 12% and
200ml, although those who did not achieve this definition
for ‘‘response’’ appeared to have lower lung function.26
Markers of asthmatic inflammation, such as eosinophils and
exhaled nitric oxide were not measured. In addition, skin
testing for atopy and serum IgE was not requested. Never-
theless, the study had also sought to mirror what remains
practical in terms of the standard diagnosis of asthma in the
community. In this regard, patients were required to have a
physician diagnosis of asthma before the age of 30 years,
must have been receiving inhaled corticosteroids for at least
1 year prior to study entry, and must have had documenta-
tion of acute bronchodilator responsiveness.
A potential limitation may relate to the focus on lung
function as an outcome rather than more in-depth measure-
ments of patient-reported outcomes. The requirement for
as-needed salbutamol, as observed, should be regarded as a
relevant measure of symptom control. Indeed, in asthma
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Figure 3 Weekly means for (a) morning peak expiratory flow
rate (l/min) and (b) evening peak expiratory flow rate (l/min) in
the tiotropium and placebo groups (po0.001 for all weeks).
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Figure 4 Weekly means for as-needed salbutamol (puffs/24 h)
in the tiotropium and placebo groups (po0.01 for all weeks).
Improvements with tiotropium in COPD patients with concomitant asthma 55guidelines, it is used as a critical basis for decisions
regarding stepping up or down pharmacotherapy.2 A reduc-
tion in the incidence of exacerbations was observed. This
effect on exacerbations is consistent with previously
reported data from clinical trials and can be regarded as a
clinically relevant patient outcome.8,9,13,22In summary, tiotropium 18mcg once daily appears
efficacious and safe in patients with COPD and concomitant
asthma. Tiotropium improved lung function and also
provided symptomatic benefits as observed with a reduction
in as-needed salbutamol and an observation suggesting a
reduction in exacerbations. Whether tiotropium is only
treating the COPD component or has some effect on the
concurrent asthma diagnosis cannot be discerned from the
present study. However, the data reinforces present guide-
lines for disease-specific treatments for asthma and COPD,
which should be encouraged in the presence of concurrent
obstructive diseases of the lung.
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